Genmab officials report on new developments

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genmab.

Report 1: Genmab A/S announced new insights into the novel mechanisms of action of its antibody HuMax-EGFr(TM) (zalutumumab). By using Protein Tomography(TM), a relatively new technology which uses an electron microscope to view the three dimensional structure of proteins on the surface of cells, HuMax-EGFr was shown to lock the EGF receptor in an inactive conformation which prevents receptor activation and the binding of growth factors. Furthermore, HuMax- EGFr was shown to inhibit EGF receptor...

Want to see the full article?

• Purchase this article for only $3.00